Loading ...
Sorry, an error occurred while loading the content.
 

HCV Testing-Marty

Expand Messages
  • 2byteme@bellsouth.net
    Quest Diagnostics Introduces Hepatitis C Virus DupliType(TM) Genotyping Assay TETERBORO, N.J., Nov. 29 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:
    Message 1 of 1 , Nov 30, 2000
      Quest Diagnostics Introduces Hepatitis C Virus DupliType(TM) Genotyping
      Assay


      TETERBORO, N.J., Nov. 29 /PRNewswire/ -- Quest Diagnostics Incorporated
      (NYSE: DGX), the nation's leading provider of gene-based medical
      testing,
      information and services, announced it has introduced HCV DupliType(TM)
      testing to provide subtyping for a broader range of hepatitis C viral
      isolates than was previously available using other technologies.

      The HCV DupliType test provides subtyping for two distinct genomic
      regions
      of the hepatitis C virus. The new test was developed by Quest
      Diagnostics'
      center for research and development and esoteric testing laboratory,
      Nichols Institute. HCV DupliType testing is exclusively offered through
      Quest Diagnostics' national laboratory network.

      The HCV DupliType test uses DNA sequencing technology to subtype two
      regions of the hepatitis C viral genome: the CORE gene and the region
      known as NS5B. Previously, only a single region was typed. This
      innovation
      allows for the detection of a broader spectrum of subtypes and the rapid

      and reliable typing of patient samples with an added degree of
      confidence.
      HCV genotyping by subtype determination is clinically relevant in
      guiding
      a physician's choice of the appropriate antiviral treatment regimen,
      including treatment duration.

      This genotyping innovation was introduced at the Association for
      Molecular
      Pathology 6th Annual Meeting in Denver. Ron M. Kagan PhD, Associate
      Scientific Director for Molecular Genetics at Quest Diagnostics' Nichols

      Institute, presented an abstracted paper on duplex subtyping of
      hepatitis
      C virus.

      Quest Diagnostics' gene-based testing focuses on infectious disease,
      oncology and hereditary conditions, and helps physicians target
      individual
      treatment regimes, monitor resistance to therapies and predict
      predisposition to various genetic conditions. Quest Diagnostics is a
      leading innovator in genomics testing, both through its research and
      development center and esoteric testing laboratory, the world-renowned
      Nichols Institute, as well as through alliances with leading academic
      and
      commercial technology developers.

      About Quest Diagnostics

      Quest Diagnostics is the nation's leading provider of diagnostic
      testing,
      information and services with annualized revenues of more than $3
      billion.
      The testing performed on human specimens helps doctors diagnose, treat
      and
      monitor disease; enables employers to detect workplace drug abuse; and
      supports pharmaceutical and biotechnology companies in clinical trials
      of
      new therapeutics worldwide. Quest Informatics analyzes laboratory and
      other medical data to help health care providers improve the care of
      patients. Additional company information can be found on the Internet
      at:
      http://www.questdiagnostics.com

      HCV DupliType is a trademark of Quest Diagnostics Incorporated.

      SOURCE Quest Diagnostics Incorporated
    Your message has been successfully submitted and would be delivered to recipients shortly.